Cargando…
Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients
BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover sign...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403711/ https://www.ncbi.nlm.nih.gov/pubmed/36032130 http://dx.doi.org/10.3389/fimmu.2022.968991 |
_version_ | 1784773440288325632 |
---|---|
author | Giannella, Alessandra Riccetti, Silvia Sinigaglia, Alessandro Piubelli, Chiara Razzaboni, Elisa Di Battista, Piero Agostini, Matteo Dal Molin, Emanuela Manganelli, Riccardo Gobbi, Federico Ceolotto, Giulio Barzon, Luisa |
author_facet | Giannella, Alessandra Riccetti, Silvia Sinigaglia, Alessandro Piubelli, Chiara Razzaboni, Elisa Di Battista, Piero Agostini, Matteo Dal Molin, Emanuela Manganelli, Riccardo Gobbi, Federico Ceolotto, Giulio Barzon, Luisa |
author_sort | Giannella, Alessandra |
collection | PubMed |
description | BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover signatures of circulating miRNAs associated with COVID-19, disease severity and mortality, small RNA-sequencing was performed on serum samples collected from 89 COVID-19 patients (34 severe, 29 moderate, 26 mild) at hospital admission and from 45 healthy controls (HC). To search for possible sources of miRNAs, investigation of differentially expressed (DE) miRNAs in relevant human cell types in vitro. RESULTS: COVID-19 patients showed upregulation of miRNAs associated with lung disease, vascular damage and inflammation and downregulation of miRNAs that inhibit pro-inflammatory cytokines and chemokines, angiogenesis, and stress response. Compared with mild/moderate disease, patients with severe COVID-19 had a miRNA signature indicating a profound impairment of innate and adaptive immune responses, inflammation, lung fibrosis and heart failure. A subset of the DE miRNAs predicted mortality. In particular, a combination of high serum miR-22-3p and miR-21-5p, which target antiviral response genes, and low miR-224-5p and miR-155-5p, targeting pro-inflammatory factors, discriminated severe from mild/moderate COVID-19 (AUROC 0.88, 95% CI 0.80-0.95, p<0.0001), while high leukocyte count and low levels of miR-1-3p, miR-23b-3p, miR-141-3p, miR-155-5p and miR-4433b-5p predicted mortality with high sensitivity and specificity (AUROC 0.95, 95% CI 0.89-1.00, p<0.0001). In vitro experiments showed that some of the DE miRNAs were modulated directly by SARS-CoV-2 infection in permissive lung epithelial cells. CONCLUSIONS: We discovered circulating miRNAs associated with COVID-19 severity and mortality. The identified DE miRNAs provided clues on COVID-19 pathogenesis, highlighting signatures of impaired interferon and antiviral responses, inflammation, organ damage and cardiovascular failure as associated with severe disease and death. |
format | Online Article Text |
id | pubmed-9403711 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-94037112022-08-26 Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients Giannella, Alessandra Riccetti, Silvia Sinigaglia, Alessandro Piubelli, Chiara Razzaboni, Elisa Di Battista, Piero Agostini, Matteo Dal Molin, Emanuela Manganelli, Riccardo Gobbi, Federico Ceolotto, Giulio Barzon, Luisa Front Immunol Immunology BACKGROUND: SARS-CoV-2 induces a spectrum of clinical conditions ranging from asymptomatic infection to life threatening severe disease. Host microRNAs have been involved in the cytokine storm driven by SARS-CoV-2 infection and proposed as candidate biomarkers for COVID-19. METHODS: To discover signatures of circulating miRNAs associated with COVID-19, disease severity and mortality, small RNA-sequencing was performed on serum samples collected from 89 COVID-19 patients (34 severe, 29 moderate, 26 mild) at hospital admission and from 45 healthy controls (HC). To search for possible sources of miRNAs, investigation of differentially expressed (DE) miRNAs in relevant human cell types in vitro. RESULTS: COVID-19 patients showed upregulation of miRNAs associated with lung disease, vascular damage and inflammation and downregulation of miRNAs that inhibit pro-inflammatory cytokines and chemokines, angiogenesis, and stress response. Compared with mild/moderate disease, patients with severe COVID-19 had a miRNA signature indicating a profound impairment of innate and adaptive immune responses, inflammation, lung fibrosis and heart failure. A subset of the DE miRNAs predicted mortality. In particular, a combination of high serum miR-22-3p and miR-21-5p, which target antiviral response genes, and low miR-224-5p and miR-155-5p, targeting pro-inflammatory factors, discriminated severe from mild/moderate COVID-19 (AUROC 0.88, 95% CI 0.80-0.95, p<0.0001), while high leukocyte count and low levels of miR-1-3p, miR-23b-3p, miR-141-3p, miR-155-5p and miR-4433b-5p predicted mortality with high sensitivity and specificity (AUROC 0.95, 95% CI 0.89-1.00, p<0.0001). In vitro experiments showed that some of the DE miRNAs were modulated directly by SARS-CoV-2 infection in permissive lung epithelial cells. CONCLUSIONS: We discovered circulating miRNAs associated with COVID-19 severity and mortality. The identified DE miRNAs provided clues on COVID-19 pathogenesis, highlighting signatures of impaired interferon and antiviral responses, inflammation, organ damage and cardiovascular failure as associated with severe disease and death. Frontiers Media S.A. 2022-08-11 /pmc/articles/PMC9403711/ /pubmed/36032130 http://dx.doi.org/10.3389/fimmu.2022.968991 Text en Copyright © 2022 Giannella, Riccetti, Sinigaglia, Piubelli, Razzaboni, Di Battista, Agostini, Dal Molin, Manganelli, Gobbi, Ceolotto and Barzon https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Immunology Giannella, Alessandra Riccetti, Silvia Sinigaglia, Alessandro Piubelli, Chiara Razzaboni, Elisa Di Battista, Piero Agostini, Matteo Dal Molin, Emanuela Manganelli, Riccardo Gobbi, Federico Ceolotto, Giulio Barzon, Luisa Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title | Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title_full | Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title_fullStr | Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title_full_unstemmed | Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title_short | Circulating microRNA signatures associated with disease severity and outcome in COVID-19 patients |
title_sort | circulating microrna signatures associated with disease severity and outcome in covid-19 patients |
topic | Immunology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9403711/ https://www.ncbi.nlm.nih.gov/pubmed/36032130 http://dx.doi.org/10.3389/fimmu.2022.968991 |
work_keys_str_mv | AT giannellaalessandra circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT riccettisilvia circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT sinigagliaalessandro circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT piubellichiara circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT razzabonielisa circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT dibattistapiero circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT agostinimatteo circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT dalmolinemanuela circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT manganelliriccardo circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT gobbifederico circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT ceolottogiulio circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients AT barzonluisa circulatingmicrornasignaturesassociatedwithdiseaseseverityandoutcomeincovid19patients |